Accelerate to discover

Back to filter

Related topics

Advances in Leukemia research using shear flow and Bioflux system

Fluxion Biosciences

May 24, 2022

Leukemia is a rare cancer with many subtypes. The production of abnormal leukocytes create disruptions in the immune...

In-vivo webinar: a versatile use of SPECT/CT in the development of theranostic tracers

MOLECUBES

Mar 9, 2022

Combining (preclinical) imaging and targeted therapy, is the basis of theranostics. In this webinar, Dr. Florea will...

Jul 5, 2022

Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing

Curiox

Oct 11, 2021

Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...

Blood-Brain Barrier (BBB) - Pathophysiology in ischemic stroke

RWD

Aug 27, 2021

In-depth Understanding of Blood-Brain Barrier (BBB)

Micro-CT user meeting 2021

Bruker Biospin

Aug 19, 2021

Year after year, the Micro-CT User meeting showcases state-of-the-art applications in both life and material sciences,...

Jul 5, 2022

Predicting single-cell gene expression with imaging flow cytometry data and machine learning

Luminex

Aug 10, 2021

High-content imaging and single-cell genomics are two of the most prominent high-throughput technologies for studying...

Show all topics (10)

Optimization of (CAR) T cell design guided by sensitive sssessment of B cell killing

Jul 10, 2017

Wednesday, July 12, 2017, 9 pm CEST.

Dan MacLeod Ph.D., Precision BioSciences, Inc.  

At Precision BioSciences, we have developed an allogeneic method using our proprietary ARCUS gene-editing technology to generate “universal” CAR T cells from healthy donors. These cells are engineered to eliminate expression of the endogenous T cell receptor making them safe for transfer to unrelated patients. By integrating the CAR transgene at a single genomic site, we can tightly control the level of CAR expression on the cell surface. We further optimize the cells by designing new CAR T constructs that include modifications to the extracellular binding domains as well as the intracellular signaling domains. Evaluating the impact of these new modifications requires sensitive methods to assay CAR T cell function. Traditional methods for evaluating cytotoxicity cannot effectively predict in vivo activity of a CAR T product; this is because they assess short-term killing potential rather than the ability to expand, persist, and exhibit serial killing. We have used the ACEA xCELLigence instrument for both B Cell Killing Assays and Leukemic Cell Killing Assays to test multiple CAR constructs with modified ectodomains, endodomains, and other modifications, and we have found this platform sensitive enough to detect subtle yet significant differences in performance not observed in traditional killing assays. Furthermore, the sensitivity of the instrument has enabled us to evaluate CAR constructs using cell numbers that are orders of magnitude lower than other assays, greatly enhancing our throughput and capabilities.

Register now

Webinar

Related technologies: Real-time, label free cell analysis

Get more info

Riccardo Pasculli

Head of application support

Riccardo

Pasculli

+420 731 127 717

Send Message

Brand profile

Agilent technologies

Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.

Related products

Located inside a tissue culture incubator, the RTCA DP Analyzer has three integrated stations for E-Plates 16 or CIM-Plates 16

show detail

Located inside a tissue culture incubator, it is capable of switching any one of the wells on the E-Plate 96 to the RTCA Analyzer for impedance measurement

show detail

Located inside a tissue culture incubator, it is capable of switching any one of the wells on any of six E-Plates to the RTCA Analyzer for impedance measurement

show detail

Instrument can be integrated with automated liquid handling platforms or a robotic plate handler from different vendors

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey